Evaluation of the Accuracy of the Use of Intravesical Prostatic Protrusion Degree as the Predictor of Benign Prostatic Hyperplasia Management

Fellyana Putri, Mohammad Fariz

Abstract

Managing symptoms of benign prostatic hyperplasia (BPH) is important but preventing the progression of the disease is also necessary. Medical therapy is commonly used to treat BPH as initial therapy. However, not every medical therapy is effective for treating BPH. Intravesical prostatic protrusion (IPP), a manifestation of BPH is used to evaluate BPH progression thus helping clinicians in choosing the effective treatment option. Patients with higher IPP degrees may experience more severe bladder outlet obstruction (BOO). They may not respond well to medical therapies, suggesting that IPP measurement can guide treatment decisions for BPH patients. This study evaluates the accuracy of using IPP degree as a predictor of BPH management by reviewing relevant literature. A comprehensive approach was undertaken, including the selection and filtering of articles from reputable databases and scholarly repositories using specific keywords related to the study's objectives. By measuring IPP degrees, the severity of clinical BPH can be categorized, allowing clinicians to choose effective treatment options and predict treatment outcomes.

Keywords

Benign Prostatic Hyperplasia, Bladder Outlet Obstruction, Intravesical Prostatic Protrusion, Management, Transabdominal Ultrasound

Full Text:

PDF

References

Kuei CH, Liao CH, Chiang BJ. Significant intravesical prostatic protrusion and prostatic calcification predict unfavorable outcomes of medical treatment for male lower urinary tract symptoms Urological Science. 2016;27(1):13-16

Gandhi J, Weissbart SJ, Kim AN, Joshi G, Kaplan SA, Khan SA. Clinical Considerations for Intravesical Prostatic Protrusion in the Evaluation and Management of Bladder Outlet Obstruction Secondary to Benign Prostatic Hyperplasia. Current Urol. 2018;12:6–12.

Eze BU, Amu OC, Edeh JA. A Review of Intravesical Prostatic Protrusion in the Evaluation and Treatment of Benign Prostatic Enlargement. European Journal of Medical and Health Sciences 2021 Jan;3(1):13-17.

Foo KT. Pathophysiology of clinical benign prostatic hyperplasia. Asian Journal of Urology. 2017;4:152-7.

Kurnia IC, Ghinorawa T, Rochadi S. Correlation of PSA, PV, and IPP in detecting BOO caused by prostate enlargement. Indonesian Journal of Urology. 2014;21:1-6.

Reddy SVK, Shaik AB. Non-invasive evaluation of bladder outlet obstruction in benign prostatic hyperplasia: a clinical correlation study, Arab J. Urol. 2019; 17(4).259-264.

Eze BU, et al. Correlation between intravesical prostatic protrusion and international prostate symptom score among Nigerian men with benign prostatic hyperplasia. Niger. J. Clin. Pract. 2019;22(4):454-9.

Mehraban D. Clinical value of intravesical prostatic protrusion in the evaluation and management of prostatic and other lower urinary tract diseases. Asian Journal of Urology. 2017;4:174-180.

Gravas S, Cornu JNC, Gacci M, et al. Management of nonneurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). European Association of Urology Guidelines. 2019.

Foo KT. Solving the benign prostatic hyperplasia puzzle. Asian J Urol. 2016;3:6–9.

Sigdel GB, Belokar WK. Clinical significance of intravesical prostatic protrusion in patients with benign prostatic hyperplasia. J UnivColl Med Sci. 2015;3:6–10.

Lee A, Lee HJ, Lim KB, Huang HH, Ho H, Foo KT. Can intravesical prostatic protrusion predict bladder outlet obstruction even in men with good flow?. Asian J. Urol. 2016;3:39-43.

Zheng J, et al. Role for intravesical prostatic protrusion in lower urinary tract symptom: a fluid structural interaction analysis study. BMC Urol. 2015;15:86.

Kim MS, Park KK, Chung BH, Lee SH. Effect of photoselective vaporization prostatectomy on lower urinary tract symptoms in benign prostatic hyperplasia with or without intravesical prostatic protrusion. Korean J. Urol. 2013;54(1):36-41.

Madersbacher S, Sampson N, Culig Z. Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review. Gerontology. 2019;65:458–464.

Budaya TN, Purnomo BB, Daryanto B, Seputra KP, Satyagraha P. IPP as predictive factor for acute urinary retention in BPH Patients. Indonesian Journal of Urology. 2014;21(1): 51-55

Kalkanli A, Tandogdu Z, Aydin M, Karaca AS, Hazar AI, Balci MBC, et al. Intravesical prostatic protrusion: a potential marker of alpha-blocker treatment success in patients with benign prostatic enlargement. Urology. 2016;88:161–165.

Tjahjodjati, Santoso J. Relationships between prostate-urethral angle, intravesical prostatic protrusion, international prostatic symptom score, and uroflowmetry in benign prostatic hyperplasia patients. Int. J. Integr. Health Sci. 2015;3(2):50-54.

Park HK, Choo GY, Chung H, Paick SH, Kim HG, Kim HS, et al. Effect of intravesical prostatic protrusion on the characteristics of lower urinary tract symptom change after 12‐week drug medication: a prospective analysis. Low Urin Tract Symptoms. 2013;5(1):1-4.

Ahmed A. Sonographic parameters predicting the outcome of patients with lower urinary tract symptoms/benign prostatic hyperplasia treated with alpha1-adrenoreceptor antagonist. Urology.2016;88:143-8.

Yoshida T, Kinoshita H, Yoshida K, Mishima T, Taniguchi H, Yanishi M, et al. Intravesical prostatic protrusion as a predicting factor for the adverse clinical outcome in patients with symptomatic benign prostatic enlargement treated with dutasteride. Urology. 2016;91:154–157.

Liu Q, Zhu Y, Liu J, Qi J, Kang J. Ultrasound image features of intravesical prostatic protrusion indicated failure of medication therapy of finasteride and doxazosin in patients with benign prostatic hyperplasia (LUTS/BPH). Int. Urol. Nephrol. 2017;46(3):399-404.

Hirayama K, Masui K, Hamada A, Shichiri Y, Masuzawa N, Hamada S. Evaluation of intravesical prostatic protrusion as a predictor of dutasteride-resistant lower urinary tract symptoms/benign prostatic enlargement with a high likelihood of surgical intervention. Urology. 2015;86:565–569.

Puthenveetil RT, Baishya D, Barua S, Sarma D. Implication of ultrasound bladder parameters on treatment response in patients with benign prostatic hyperplasia under medical management. Asian J. Urol. 2015;2(4):233-7.

Cumpanas AA, Botoca M, Minciu R, BucurasV. Intravesical prostatic protrusion can be a predicting factor for the treatment outcome in patients with lower urinary tract symptoms due to benign prostatic obstruction treated with tamsulosin. Urology. 2013;81:859–863.

Kaplan SA. Re: intravesical prostatic protrusion can be a predicting factor for the treatment outcome in patients with lower urinary tract symptoms due to benign prostatic obstruction treated with tamsulosin. J Urol. 2014;191:157.

Kim BS, Ko YH, Song PH, Kim TH, Kim KH, Kim BH. Prostatic urethral length as a predictive factor for surgical treatment of benign prostatic hyperplasia: a prospective, multiinstitutional study. Prostate Int.2019;7(1):30-34.

Topazio L, Perugia C, Nunzio CD, Gaziev G, Lacovelli V, Bianchi D, et al. Intravesical prostatic protrusion is a predictor of alpha blockers response: results from an observational study. BMC Urology. 2018;18:6.

Eze BU. Intravesical prostatic protrusion as a predictor of need for surgical therapy in benign prostatic hyperplasia patients.European Journal of Medical and Health Sciences. 2023;5(3):9-13.

Kuo TL, Teo JS, Foo KT. The role of intravesical prostatic protrusion (IPP) in the evaluation and treatment of bladder outlet obstruction (BOO). Neurourol Urodyn. 2016 Apr;35(4):535-7.

Jo JK, Hong SK, Byun SS, Zargar H, Autorino R, Lee SE: Urinary continence after robot-assisted laparoscopic radical prostatectomy: the impact of intravesical prostatic protrusion. Yonsei Med J. 2016;57:1145–1151.

Foo KT. What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)? World Journal of Urology. 2019 Jul;37(7):1293-1296.

DOI: https://doi.org/10.26891/JIK.v18i1.2024.11-16

Refbacks

  • There are currently no refbacks.